GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » EV-to-FCF

INBX (Inhibrx Biosciences) EV-to-FCF : -1.15 (As of Jul. 12, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Inhibrx Biosciences's Enterprise Value is $193.71 Mil. Inhibrx Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-168.75 Mil. Therefore, Inhibrx Biosciences's EV-to-FCF for today is -1.15.

The historical rank and industry rank for Inhibrx Biosciences's EV-to-FCF or its related term are showing as below:

INBX' s EV-to-FCF Range Over the Past 10 Years
Min: -1.27   Med: -0.31   Max: 0.26
Current: -1.15

During the past 3 years, the highest EV-to-FCF of Inhibrx Biosciences was 0.26. The lowest was -1.27. And the median was -0.31.

INBX's EV-to-FCF is ranked worse than
100% of 388 companies
in the Biotechnology industry
Industry Median: 8.605 vs INBX: -1.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-12), Inhibrx Biosciences's stock price is $21.77. Inhibrx Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $116.750. Therefore, Inhibrx Biosciences's PE Ratio (TTM) for today is 0.19.


Inhibrx Biosciences EV-to-FCF Historical Data

The historical data trend for Inhibrx Biosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences EV-to-FCF Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
EV-to-FCF
- - -0.40

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.08 -0.15 -0.40 -0.55

Competitive Comparison of Inhibrx Biosciences's EV-to-FCF

For the Biotechnology subindustry, Inhibrx Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx Biosciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's EV-to-FCF falls into.


;
;

Inhibrx Biosciences EV-to-FCF Calculation

Inhibrx Biosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=193.714/-168.753
=-1.15

Inhibrx Biosciences's current Enterprise Value is $193.71 Mil.
Inhibrx Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-168.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibrx Biosciences  (NAS:INBX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Inhibrx Biosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21.77/116.750
=0.19

Inhibrx Biosciences's share price for today is $21.77.
Inhibrx Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $116.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Inhibrx Biosciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.